Dykema Gossett PLLC

Cannabis Law Blog

Posts by David P. Graham

Cannabis Law Blog

News and analysis focusing on the full spectrum of cannabis-related issues facing businesses, investors, financial institutions and all levels of government throughout the United States

Contributors

Photo of Cannabis Law Blog David P. Graham
Senior Counsel
dgraham@dykema.com
612-486-1521
View Bio

Showing 6 posts by David P. Graham.

FDA Sends CBD Warning to Ex-NFLer making COVID-19 Claims

Neuro XPF, a company which sells CBD was ordered to stop selling its CBD products by the FDA because it make claims related to preventing the contraction of COVID-19.

Neuro XPF stated that “your best defense against the COVID-19 blitz starts with a strong immune system.” Kyle Turley also has been tweeting that CBD can “prevent and cure” the coronavirus as well as “other diseases.” Read More ›

FDA Work Related Cannabidiol Products Update

On March 5, 2020 the FDA sent out a notice about work being done on Cannabidiol products. The announcement seeks information from the public in the form of research about the effects of Cannabidiol products. The FDA is reopening the public docket established in May 2019 for the submission of data related to the efficacy and safety of Cannabidiol. The docket includes a mechanism for stakeholders to submit data and information that is confidential.  Read More ›

More FDA Warning Letters for CBD Sellers

On November 25, 2019 the FDA sent 15 more warning letters to CBD product manufacturers and sellers regarding the content and labeling of their products. For the most part, the warnings relate to claims made about the products which the FDA concludes make the products new drugs because they claim to cure or prevent a disease. Some of the claims include: Read More ›

FDA Again Warns CBD Product Manufacturer

On July 22, 2019 the FDA sent a warning letter to Curaleaf, Inc. warning it about the labeling and marketing of its CBD products including lotion, patches, tinctures, disposable vape pen, and pet products. FDA concluded that Curaleaf’s websites, social media and other marketing material made unsupported health claims about its products, in violation of FDA regulations.  Read More ›

CBD Warning Letter

FDA sent warning letters dated March 28 to three companies marketing CBD products with what FDA describes as “egregious and unfounded claims that are aimed at vulnerable populations.” The companies which received warning letters sell hemp oil, CBD soft gels, CBD crystal isolate and other related products. Read More ›

FDA Statement on Cannabis-Containing and Cannabis-Derived Products

On April 2, 2019, the FDA further described its upcoming effort to regulate or at least discuss the regulation of cannabis-containing and cannabis-derived products. The FDA reiterated its power as given to it by the 2018 Farm Bill to regulate cannabis products and to ensure that they are used and sold safely in drugs, dietary supplements and conventional food. Read More ›